Botulinum neurotoxins (BoNTs) are extremely toxic and have been deemed a Tier 1 potential bioterrorism agent. The most potent and persistent of the BoNTs is the "A" serotype, with strategies to counter its etiology focused on designing small molecule inhibitors of its light chain (LC), a zincdependent metalloprotease. However, the successful structure-based drug design (SBDD) of inhibitors has been confounded as the LC is highly flexible with significant morphological changes occurring upon inhibitor binding. To achieve greater success, previous and new co-crystal structures were evaluated from the standpoint of inhibitor enantioselectivity and their effect on active-site morphology.Based upon these structural insights, a previously unknown hydrophobic sub-pocket adjacent to the S1' site was discovered and used to design inhibitors that take advantage of π-π stacking interactions.Structure-activity relationships (SARs) were defined and X-ray crystal structures and docking models were examined to rationalize the observed potency differences between inhibitors. The structure-guided design of inhibitors that utilize both the cryptic hydrophobic sub-pocket and the essential aspects to enantiomer selectivity provide a new avenue for ablating BoNT/A protease activity.